A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings-A randomised blind study

Vaccine

Volumn 29, Issue 49, 2011, Pages 9214-9223

  Gildea, Sarah ^a   Arkins, Sean ^b   Walsh, Cathal ^c   Cullinane, Ann ^a  

^a IRISH EQUINE CENTRE   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antibody; Comparison; Equine influenza; Thoroughbred; Vaccine

Indexed keywords

DUVAXYN IE-T PLUS; DUVAXYN IET PLUS; EQUILIS PREQUENZA TE; EQUILIS RESEQUIN; EQUINE INFLUENZA VACCINE; EQUIP FT; INFLUENZA VACCINE; PROTEQFLU TE; PROTEQFLU-TE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; EQUINE INFLUENZA; FARM ANIMAL; FEMALE; HEMOLYSIS; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N8; INFLUENZA VIRUS A H7N7; INTERMETHOD COMPARISON; IRELAND; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVACCINATION; SEROCONVERSION; STUD;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HORSE DISEASES; HORSES; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; IRELAND; MALE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 82555169598     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.101     Document Type: Article

References (46)

1. OIE Bulletin. Expert surveillance panel of equine influenza vaccines-conclusions and recommendations. Amelia Island, FL, USA; 2010: February 2, 2010, p. 44-5.
2. Daly J.M., Yates R.J., Browse G., Swann Z., Newton J.R., Jessett D., et al. Comparison of hamster and pony challenge models for evaluation of effect of antigenic drift on cross protection afforded by equine influenza vaccines. Equine Vet J 2003, 35(5):458-462.
3. Park A.W., Wood J.L., Daly J.M., Newton J.R., Glass K., Henley W., et al. The effects of strain heterology on the epidemiology of equine influenza in a vaccinated population. Proc Biol Sci 2004, 271(1548):1547-1555.
4. Cullinane A., Elton D., Mumford J. Equine influenza-surveillance and control. Influenza Other Respi Viruses 2010, 4(6):339-344.
5. Guthrie A.J., Stevens K.B., Bosman P.P. The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Rev Sci Tech 1999, 18(1):179-185.
6. King E.L., Macdonald D. Report of the Board of Inquiry appointed by the Board of the National Horseracing Authority to conduct enquiry into the causes of the equine influenza which started in the Western cape in early December 2003 and spread to the Eastern Cape and Gauteng. Aust Equine Vet 2004, 23:139-142.
7. Uppal P.K., Yadav M.P., Oberoi M.S. Isolation of A/Equi-2 virus during 1987 equine influenza epidemic in India. Equine Vet J 1989, 21(5):364-366.
8. Powell D.G., Watkins K.L., Li P.H., Shortridge K.F. Outbreak of equine influenza among horses in Hong Kong during 1992. Vet Rec 1995, 136(21):531-536.
9. Garner M.G., Cowled B., East I.J., Moloney B.J., Kung N.Y. Evaluating the effectiveness of early vaccination in the control and eradication of equine influenza-a modelling approach. Prev Vet Med 2011, 99(1):15-27.
10. Turf Club rules of racing and Irish National Steeplechase rules 2010 2010, Publisher's Office: Office of the Governing Bodies, The Curragh, Co., Kildare, p. 50-7.
11. Federation Equestre Internationale. HM King Hussein Building, Chemin des Delices 9, 1006 Lausanne, Switzerland. http://www.horsesport.org/veterinary/vaccinations-and-health-requirements.
12. Mumford J.A., Jessett D.M., Rollinson E.A., Hannant D., Draper M.E. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet Rec 1994, 134(7):158-162.
13. Mumford J.A., Wilson H., Hannant D., Jessett D.M. Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiol Infect 1994, 112(2):421-437.
14. Heldens J.G., Pouwels H.G., Derks C.G., Van de Zande S.M., Hoeijmakers M.J. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine 2009, 27(40):5530-5537.
15. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 2005, 156(12):367-371.
16. Mumford J.A., Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand 1992, 79:137-146.
17. Mumford J.A. Biology, epidemiology and vaccinology of equine influenza. Quality control of equine influenza vaccines. Proceedings of an international symposium organised by the European Directorate for the Quality of Medicines (EDQM) 2001, 7-12.
18. Mumford J. Collaborative study for the establishment of three European Pharmacopoeia Biological Reference Preparations for equine influenza horse antiserum. Pharmeuropa 2000, 7-21.
19. Daly J., Daas A., Behr-Gross M.E. Collaborative study for the establishment of a candidate equine influenza subtype 2 American-like strain A/EQ/South Africa/4/03-horse antiserum biological reference preparation. Pharmeuropa Bio 2007, 1:7-14.
20. European Agency for the Evaluation of Medicinal Produces (EMEA), Committee for Veterinary Medicinal Products (CVMP). Note for Guidance 1998: harmonisation of requirements for equine influenza vaccines specific requirements for substitution or addition of a strain or strains. Document EMEA/CVMP/112/98-FINAL. London, UK: EMEA.
21. Newton J.R., Townsend H.G., Wood J.L., Sinclair R., Hannant D., Mumford J.A. Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J 2000, 32(1):65-74.
22. Gildea S., Arkins S., Walsh C., Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt Horses-a randomised blind study. Vaccine 2011, 29(22):3917-3922.
23. Heldens J.G., Weststrate M.W., van den Hoven R. Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines-a retrospective analysis of three independent field trials. J Immunol Methods 2002, 264(1-2):11-17.
24. Mumford J.A., Jessett D., Dunleavy U., Wood J., Hannant D., Sundquist B., et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994, 12(9):857-863.
25. Cullinane A., Weld J., Osborne M., Nelly M., McBride C., Walsh C. Field studies on equine influenza vaccination regimes in thoroughbred foals and yearlings. Vet J 2001, 161(2):174-185.
26. Holmes M.A., Townsend H.G., Kohler A.K., Hussey S., Breathnach C., Barnett C., et al. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus. Vet Immunol Immunopathol 2006, 111(1-2):67-80.
27. Heldens J.G., Van de Wouw J.C., Van Loon A.A. An updated equine influenza vaccine and an equine influenza-herpesvirus combination vaccine containing an immunostim adjuvant provoke equal antibody levels in young foals throughout the primary vaccination course. Vet J 2002, 164(3):288-291.
28. Paillot R., Grimmett H., Elton D., Daly J.M. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 2008, 39(3):21.
29. Paillot R., Kydd J.H., MacRae S., Minke J.M., Hannant D., Daly J.M. New assays to measure equine influenza virus-specific Type 1 immunity in horses. Vaccine 2007, 25(42):7385-7398.
30. Adams A.A., Sturgill T.L., Breathnach C.C., Chambers T.M., Siger L., Minke J.M., et al. Humoral and cell-mediated immune responses of old horses following recombinant canarypox virus vaccination and subsequent challenge infection. Vet Immunol Immunopathol 2011, 139(2-4):128-140.
31. Newton J.R., Lakhani K.H., Wood J.L., Baker D.J. Risk factors for equine influenza serum antibody titres in young thoroughbred racehorses given an inactivated vaccine. Prev Vet Med 2000, 46(2):129-141.
32. Barquero N., Daly J.M., Newton J.R. Risk factors for influenza infection in vaccinated racehorses: lessons from an outbreak in Newmarket, UK in 2003. Vaccine 2007, 25(43):7520-7529.
33. Van Oirschot J.T., Bruin G., de Boer-Luytze E., Smolders G. Maternal antibodies against equine influenza virus in foals and their interference with vaccination. Zentralbl Veterinarmed B 1991, 38(5):391-396.
34. van Maanen C., Bruin G., de Boer-Luijtze E., Smolders G., de Boer G.F. Interference of maternal antibodies with the immune response of foals after vaccination against equine influenza. Vet Q 1992, 14(1):13-17.
35. Wilson W.D., Mihalyi J.E., Hussey S., Lunn D.P. Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 2001, 33(7):644-650.
36. Gildea S., Arkins S., Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus. Influenza Other Respi Viruses 2010, 4(6):363-372.
37. Holland R.E., Conboy H.S., Berry D.B., Fallon E.H., Powell D.G., Tudor L.R., Chambers T.M. Age dependence of foal vaccination for equine influenza: new evidence from USA. Equine infectious diseases VIII 1999, R&W Ltd., Newmarket.
38. Minke J.M., Toulemonde C.E., Dinic S., Cozette V., Cullinane A., Audonnet J.C. Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine. J Comp Pathol 2007, 137(Suppl. 1):S76-S80.
39. Wood JLN. A review of the history and epidemiology and a description of recent outbreak. MSc dissertation. London: University of London; 1991.
40. Mumford J.A. Control of influenza from an international perspective. Equine infectious diseases VIII 1999, R&W Ltd., Newmarket, p. 11-24.
41. Heldens J.G., Pouwels H.G., van Loon A.A. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). Vet J 2004, 167(2):150-157.
42. Bryant N.A., Paillot R., Rash A.S., Medcalf E., Montesso F., Ross J., et al. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak. Vet Res 2010, 41(2):19.
43. Bernstein D.I., Zahradnik J.M., DeAngelis C.J., Cherry J.D. Influenza immunization in children and young adults: clinical reactions and total and IgM antibody responses after immunization with whole-virus or split-product influenza vaccines. Am J Dis Child 1982, 136(6):513-517.
44. Mumford J.A. Progress in the control of influenza. Equine Infectious Diseases VI, Proceedings of the 6th international conference 1992, 207-217.
45. Heldens J.G., Kersten A.J., Weststrate M.W., van den Hoven R. Duration of immunity induced by an adjuvanted and inactivated equine influenza: tetanus and equine herpesvirus 1 and 4 combination vaccine. Vet Q 2001, 23(4):210-217.
46. Anonymous Equine influenza vaccine (inactivated). European pharmacopoeia 2001, European Department for the Quality of Medicines, Strassbourg, France. 5th ed.